Management of the Anemia of Prematurity Using Human Recombinant Erythropoietin

comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity

BACKGROUND Premature neonates are at risk for severe anemia and erythropoietin is the most important hormone in erythropoiesis. The aim of this study was to evaluate the influence of oral recombinant human erythropoietin (rhEPO) in proving erythropoiesis in neonates. METHODS This was a randomized clinical trial study. Thirty neonates were enrolled from September 2007 to September 2008. The fi...

[The effect of recombinant human erythropoietin on the treatment of anemia of prematurity]

OBJECTIVE: To assess the efficacy of erythropoietin in the prevention and treatment of anemia of prematurity, correlating the use of this drug with weight gain, length, and head circumference and comparing two administration schemes of he same weekly dose: daily use and twice a week. METHODS: The study comprised 42 premature newborns with gestational age up to 33 weeks, birthweight up to 1550 g...

"effect of high versus low doses of human recombinant erythropoietin on the anemia of prematurity"

recombinant human erythropoietin (rh-epo) is known to accelerate erythropoiesis in preterm infants. the purpose of this study was to compare the effectiveness of early treatment with two doses of rh-epo (high vs. low dose) in the management of anemia of prematurity. twenty preterm infants with hematocrit (hct) < 30% when infant’s age was between 2 to 3 weeks after birth or hct <25% when infant’...

Recombinant Human Erythropoietin in Cancer-Related Anemia

The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an improvement in hemoglobin and hematocrit, a reduction in transfusion requirements, and improvement in quality-of-life (QOL) end points. Based o...